Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Bozkurt, Latife ^a   Göbl, Christian S ^a   Tura, Andrea ^b   Chmelik, Marek ^a   Prikoszovich, Thomas ^a   Kosi, Lana ^a   Wagner, Oswald ^a   Roden, Michael ^c   Pacini, Giovanni ^b   Gastaldelli, Amalia ^d   Kautzky Willer, Alexandra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CNR   (Italy)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FATTY ACID; FIBRINOGEN; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; LIPID;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FATTY LIVER; FATTY LIVER INDEX; FEMALE; HEPATOBILIARY PARAMETERS; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREGNANCY DIABETES MELLITUS; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY ANALYSIS; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; GLUCOSE TOLERANCE TEST; KINETICS; METABOLISM; PREGNANCY; REGRESSION ANALYSIS;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; DISEASE PROGRESSION; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; KINETICS; LIPIDS; PREGNANCY; REGRESSION ANALYSIS;

EID: 84857674421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032710     Document Type: Article

References (35)

1. Retnakaran R, Qi Y, Connelly P, Sermer M, Zinman B, et al. (2010) Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. J Clin Endocrinol Metab 95: 670-677.
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: 1844-1850.
3. Musso G, Gambino R, Bo S, Uberti B, Biroli G, et al. (2008) Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 31: 562-568.
4. Targher G, Day C, Bonora E, (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363: 1341-1350.
5. Winzer C, Wagner O, Festa A, Schneider B, Roden M, et al. (2004) Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27: 1721-1727.
6. Farhan S, Winzer C, Tura A, Quehenberger P, Bieglmaier C, et al. (2006) Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes. Eur J Clin Invest 36: 345-352.
7. Prikoszovich T, Winzer C, Schmid AI, Szendroedi J, Chmelik M, et al. (2011) Body and Liver Fat Mass Rather Than Muscle Mitochondrial Function Determines Glucose Metabolism in Women with a History of Gestational Diabetes. Diabetes Care Feb;34 (2): 430-6 Epub 2010 Oct 26.
8. Roden M, (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes- pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335-48.
9. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, et al. (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33.
10. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, et al. (2009) Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49: 1537-1544.
11. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F, et al. (2010) Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 10: 56.
12. Rückert IM, Heier M, Rathmann W, Baumeister SE, Döring A, et al. (2011) Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study. PLoS One 6 (8): e22932.
13. Lerchbaum E, Gruber HJ, Schwetz V, Giuliani A, Moeller R, et al. (2011) Fatty Liver Index in Polycystic Ovary Syndrome. Eur J Endocrinol Sep 21 doi:10.1530/EJE-11-0614.
14. Metzger B, Coustan D, (1998) Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee Diabetes Care 21 (Suppl 2): B161-167.
15. Pacini G, Tonolo G, Sambataro M, Maioli M, Ciccarese M, et al. (1998) Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol 274: E592-599.
16. Kautzky-Willer A, Krssak M, Winzer C, Pacini G, Tura A, et al. (2003) Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes. Diabetes 52: 244-251.
17. Mari A, Pacini G, Murphy E, Ludvik B, Nolan J, (2001) A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24: 539-548.
18. Szendroedi J, Schmid AI, Chmelik M, Toth C, Brehm A, et al. (2007) Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 4 (5): e154.
19. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, et al. (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168: 1609-1616.
20. Magkos F, Fabbrini E, Mohammed B, Patterson B, Klein S, (2010) Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 18: 1510-1515.
21. Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, et al. (2004) Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47: 1360-1369.
22. Kautzky-Willer A, Handisurya A, (2009) Metabolic diseases and associated complications: sex and gender matter! Eur J Clin Invest 39: 631-648.
23. Forbes S, Taylor-Robinson SD, Patel N, Allan P, Walker BR, et al. (2011) Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia 54 (3): 641-7.
24. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C, et al. (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14: 72-81.
25. Dowman JK, Tomlinson JW, Newsome PN, (2010) Pathogenesis of non-alcoholic fatty liver disease. QJM 2010 Feb;103 (2): 71-83.
26. Szendroedi J, Chmelik M, Schmid AI, Nowotny P, Brehm A, et al. (2009) Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 50 (4): 1079-86.
27. Gastaldelli A, Harrison S, Belfort-Aguilar R, Hardies L, Balas B, et al. (2009) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50: 1087-1093.
28. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, et al. (2005) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48: 634-642.
29. Van Gaal L, Mertens I, De Block C, (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880.
30. Alessi M, Bastelica D, Mavri A, Morange P, Berthet B, et al. (2003) Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 23: 1262-1268.
31. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, et al. (1996) Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men-role of the metabolic syndrome. Thromb Haemost 76: 69-73.
32. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, et al. (2010) Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 32: 769-775.
33. Marra F, Bertolani C, (2009) Adipokines in liver diseases. Hepatology 50: 957-969.
34. Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, et al. (2009) Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 44: 1064-1070.
35. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, et al. (2011) Fatty liver index (FLI) and mortality: The cremona study at the 15(th) year of follow up. Hepatology.Apr 12. doi: 10.1002/hep.24356.